The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) announced on Dec 2, 2025 that the UAMS Winthrop P. Rockefeller Cancer Institute joined the Caris Precision Oncology Alliance (Caris POA).
The Caris POA now includes 98 centers, including 45 NCI‑designated cancer centers. Members gain access to Caris' multimodal molecular profiling (genomic, transcriptomic, proteomic) and a large matched clinico‑genomic database containing data from hundreds of thousands of cancer patients with tens of billions of data points per patient to support biomarker‑driven research and trial matching.
Positive
- Network size: Caris POA now comprises 98 centers
- NCI presence: 45 NCI‑designated cancer centers in network
- Database scale: matched data from hundreds of thousands of patients
Negative
- None.
Insights
Joining Caris POA expands UAMS access to a large multimodal database and collaborative biomarker research, with modest near-term commercial impact.
The addition of the UAMS Winthrop P. Rockefeller Cancer Institute to the Caris Precision Oncology Alliance increases the network to 98 institutions, including 45 NCI-designated cancer centers, enabling shared use of Caris molecular profiling across genomic, transcriptomic and proteomic modalities. This creates more standardized molecular testing inputs for collaborative research and gives UAMS clinicians access to Caris' large multi-modal database containing matched molecular and clinical outcomes from hundreds of thousands of patients.
Key dependencies and risks include the practical integration of data and workflows between UAMS and Caris, the actual uptake of Caris profiling in clinical pathways at UAMS, and the extent to which biopharma-sponsored, biomarker-directed trials are opened to UAMS patients. The announcement states members can participate in an expanding range of such trials but gives no concrete enrollment commitments or timelines.
Watch for measurable signs of impact over the next 6–24 months: uptake rates of Caris molecular profiling at UAMS, participation in any named biomarker-directed trials, and any reported changes in clinical trial referrals or published collaborative research. These near-term metrics will indicate whether the collaboration translates into broader clinical or commercial value.
"It is great to welcome UAMS to the Caris POA. Their unwavering commitment to excellence perfectly aligns with our commitment to advance biomarker-driven precision oncology," said James Hamrick, MD, MPH, Chairman of the Caris POA. "Together, we will leverage shared data and cutting-edge AI to accelerate research and translate it into personalized care for patients in
Caris POA members establish and refine molecular testing standards through collaborative research designed to improve clinical outcomes for cancer patients. By harnessing Caris' advanced AI-driven bioinformatics and machine learning platform and a vast multi-modal database, the Caris POA accelerates discovery and translates innovative findings into more effective, personalized patient care.
The Winthrop P. Rockefeller Cancer Institute at the University of
"Joining the Caris Precision Oncology Alliance strengthens our ability to bring the most advanced, data-driven cancer care to patients in
With the newest addition, the Caris POA now comprises 98 cancer centers, academic institutions, research consortia, and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Using Caris molecular profiling, which includes comprehensive genomic, transcriptomic, and proteomic data, Caris aims to empower its network to prioritize therapeutic options and identify beneficial clinical trial opportunities for patients. Caris POA members can also participate in an expanding range of biomarker-directed trials sponsored by biopharmaceutical companies. Furthermore, Caris POA institutions have access to one of the industry's largest and most detailed multi-modal databases, containing matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, with tens of billions of data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in
About University of
UAMS is the state's only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; a hospital; a main campus in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on or about November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
UAMS Media:
Leslie W. Taylor, 501-686-8998
Wireless phone: 501-951-7260
leslie@uams.edu
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-uams-winthrop-p-rockefeller-cancer-institute-302629788.html
SOURCE Caris Life Sciences
FAQ
What did Caris announce about UAMS on Dec 2, 2025 (CAI)?
How many centers are in the Caris POA after UAMS joined (CAI)?
How many NCI‑designated centers are in the Caris POA (CAI)?
What types of molecular data does Caris provide to POA members (CAI)?
How large is the Caris clinico‑genomic database available to POA members (CAI)?
Will UAMS participation affect clinical trial access for patients in Arkansas (CAI)?
